Trevi Therapeutics, Inc.

NasdaqGM TRVI

Trevi Therapeutics, Inc. Market Capitalization on February 05, 2025: USD 376.23 M

Trevi Therapeutics, Inc. Market Capitalization is USD 376.23 M on February 05, 2025, a 249.73% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

Trevi Therapeutics, Inc. 52-week high Market Capitalization is USD 410.19 M on January 03, 2025, which is 9.03% above the current Market Capitalization.
Trevi Therapeutics, Inc. 52-week low Market Capitalization is USD 112.19 M on February 06, 2024, which is -70.18% below the current Market Capitalization.
Trevi Therapeutics, Inc. average Market Capitalization for the last 52 weeks is USD 241.38 M.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

NasdaqGM: TRVI

Trevi Therapeutics, Inc.

CEO	Ms. Jennifer L. Good
IPO Date	May 7, 2019
Location	United States
Headquarters	195 Church Street
Employees	27
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Clinical Trials Drugstores & Retail Pharmacies Personal Care

Description

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Key trends

Past 5 years